INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
04/01/2026
Back to search
Official data from USPTO
VACSAF
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
04/02/2026
Trademark type
Word
Nice classes
1, 5
Filing date
10/27/2017
Registration date
01/15/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/01/2025
Last transaction
04/02/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Belfast Co. Antrim BT3 9DT, GB
Examiner
MAYER, DAVID COREY
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
SISAF Ltd
Representatives
Helen Hill Minsker Banner & Witcoff, Ltd.
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals and chemical preparations for use in industryscience and research; Biochemical substances and biochemical preparations for use in industryscience and researchexcipients for use in the manufacture of pharmaceutical preparationscosmetic preparationsnutraceutical preparationsveterinary preparationsdietary supplementsfoods and pharmaceutical preparations for topical use; Chemical preparations for pharmaceuticalmedical and veterinary research in the nature of reagents and substrateschemical compounds for use in patterning at nano scale or near nano scale; Silicon for use in industryscience and research; Silicon nanoparticle materialssilicon and silicon-based chemical compounds for use in industryscience and research; Porous silicon nanoparticle materialssilicon and silicon-based chemical compounds for use in industryscience and research; Chemical materialschemical catalysts for carrying and delivery of chemicalbiochemical and biological substances for use in industry and not for medical or veterinary use; Silicon for use in stabilising enzymes of chemicalbiochemical and biological substances for scientific research purposes; Nanoparticle materialssilicon-based chemical compounds for use in stabilising enzymes of chemicalbiochemical and biological substances for scientific research purposes; Silicon nanoparticle materials being silicon-based chemical compounds for use in stabilising enzymes of chemicalbiochemical and biological substances for scientific research purposes; Porous silicon nanoparticle materials being silicon-based chemical compounds for stabilising enzymes of chemicalbiochemical and biological substances for use in industry and for scientific research purposes; Chemicals and chemical preparationsreagents and catalysts for pharmaceutical research purposes; Chemicals and chemical preparationsreagents and catalysts for scientific research in the field of medicineveterinary and pharmaceutics; Excipient for use in the manufacture of pharmaceutical productsincluding for the manufacture of vaccines and veterinary preparations
Class 5
Antiviral pharmaceutical preparationsanti-infective pharmaceutical preparationsanti-inflammatory pharmaceutical preparationsantiseptic pharmaceutical preparationsantibacterial pharmaceutical preparationsantibiotic pharmaceutical preparationsantifungal pharmaceutical preparationsanti-fibrotic pharmaceutical preparations; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disordersmusculoskeletal diseases and disordersinflammatory diseases and disordersrespiratory diseases and disorderspulmonary diseases and disordersimmune system related diseases and disordershematological diseases and disordersoncological diseases and disordersurological diseases and disordersgastro-intestinal diseaseseye diseases and conditionsheart rhythm disorderskidney diseasesnephropathic diseaseshematological disordersdiabeteshypertensionskin disordersdamaged skin and tissuewrinkleswounds and allergiesinsect bitesdermatological diseases and disordersHIVcancer and tumorsbone diseasesarthritiscardiopulmonary diseases and disordersinfectious diseasesblood disorderspainsepsisalopeciaobesitycognitive disorders and diseasesneurological disordershormonal disordersdisorders of the autoimmune systemmetabolic system diseases and disordersendocrine system diseases and disordersgenitourinary system diseases and disorders; Preparations in the nature of animal feed supplements containing trace elements; Preparations in the nature of human vaccine preparations containing trace elements; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticalsnutraceutical and veterinary products; Drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceuticalnutraceutical and veterinary products; Drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceuticalnutraceutical and veterinary products; Drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceuticalnutraceutical and veterinary products; drug delivery agents consisting of compounds for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical vaccines; Drug delivery agents consisting of compounds for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemicalbiochemicalbiologicalpharmaceutical antibiotics; Chemicalbiochemicalbiological and pharmaceutical substances for medicinal use being pharmaceutical preparation stabilizers
Publications
History of USPTO decisions and trademark events.
33 publications found
C71T
CANCELLED SECTION 71
08/01/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/15/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/17/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/01/2019
FIMP
FINAL DISPOSITION PROCESSED
04/30/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/15/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
01/15/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/14/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/30/2018
PUBO
PUBLISHED FOR OPPOSITION
10/30/2018
GPNX
NOTIFICATION PROCESSED BY IB
10/26/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/10/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/10/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/10/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/18/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
09/18/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/18/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
09/18/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/18/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/31/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/31/2018
ALIE
ASSIGNED TO LIE
08/30/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/15/2018
RFNT
REFUSAL PROCESSED BY IB
03/09/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/16/2018
RFRR
REFUSAL PROCESSED BY MPU
02/16/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/13/2018
CNRT
NON-FINAL ACTION WRITTEN
02/12/2018
DOCK
ASSIGNED TO EXAMINER
02/06/2018
MAFR
APPLICATION FILING RECEIPT MAILED
11/29/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/25/2017
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
11/16/2017
Continuous trademark protection
Get notified about every new filing that threatens VACSAF or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.